Nikhil Wagle

19PUBLICATIONS
190CO-AUTHORS
Molecular targetsPredictive and prognostic markersCentral nervous systemGene expression (incl. microarray and other genome-wide approaches)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Mar 29, 2025
Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.

Johanna Klughammer, Daniel L Abravanel, Åsa Segerstolpe

|Oct 31, 2024
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.

Johanna Klughammer, Daniel L Abravanel, Åsa Segerstolpe

|Mar 21, 2024
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.

Erica L Mayer, Yue Ren, Nikhil Wagle

|Mar 20, 2024
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.

Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain

|Jun 26, 2023
Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab.

Marla Lipsyc-Sharf, Esha Jain, Laura C Collins

Pageof 4

Frequent Collaborators

5 joint publications

Sara M Tolaney

5 joint publications

Daniel L Abravanel

4 joint publications

Ann Partridge

4 joint publications

Jorge Gomez Tejeda Zanudo